Literature DB >> 16810473

ESH-ESC guidelines for the management of hypertension.

Serap Erdine1, Oben Ari, A Zanchetti, R Cifkova, R Fagard, S Kjeldsen, G Mancia, N Poulter, K H Rahn, J L Rodicio, L M Ruilope, J Staessen, P van Zwieten, B Waeber, B Williams.   

Abstract

The following is a brief statement of the 2003 European Society of Hypertension (ESH)-European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. The continuous relationship between the level of blood pressure and cardiovascular risk makes the definition of hypertension arbitrary. Since risk factors cluster in hypertensive individuals, risk stratification should be made and decision about the management should not be based on blood pressure alone, but also according to the presence or absence of other risk factors, target organ damage, diabetes, and cardiovascular or renal damage, as well as on other aspects of the patient's personal, medical and social situation. Blood pressure values measured in the doctor's office or the clinic should commonly be used as reference. Ambulatory blood pressure monitoring may have clinical value, when considerable variability of office blood pressure is found over the same or different visits, high office blood pressure is measured in subjects otherwise at low global cardiovascular risk, there is marked discrepancy between blood pressure values measured in the office and at home, resistance to drug treatment is suspected, or research is involved. Secondary hypertension should always be investigated. The primary goal of treatment of patient with high blood pressure is to achieve the maximum reduction in long-term total risk of cardiovascular morbidity and mortality. This requires treatment of all the reversible factors identified, including smoking, dislipidemia, or diabetes, and the appropriate management of associated clinical conditions, as well as treatment of the raised blood pressure per se. On the basis of current evidence from trials, it can be recommended that blood pressure, both systolic and diastolic, be intensively lowered at least below 140/90 mmHg and to definitely lower values, if tolerated, in all hypertensive patients, and below 130/80 mmHg in diabetics. Lifestyle measures should be instituted whenever appropriate in all patients, including subjects with high normal blood pressure and patients who require drug treatment. The purpose is to lower blood pressure and to control other risk factors and clinical conditions present. In most, if not all, hypertensive patients, therapy should be started gradually, and target blood pressure achieved progressively through several weeks. To reach target blood pressure, it is likely that a large proportion of patients will require combination therapy with more than one agent. The main benefits of antihypertensive therapy are due to lowering of blood pressure per se. There is also evidence that specific drug classes may differ in some effect or in special groups of patients. The choice of drugs will be influenced by many factors, including previous experience of the patient with antihypertensive agents, cost of drugs, risk profile, presence or absence of target organ damage, clinical cardiovascular or renal disease or diabetes, patient's preference.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16810473     DOI: 10.1007/s00059-006-2829-3

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  17 in total

1.  Hypertension and lifestyle modification: how useful are the guidelines?

Authors:  Rachel Nicoll; Michael Y Henein
Journal:  Br J Gen Pract       Date:  2010-12       Impact factor: 5.386

2.  Comparison of combined aerobic and high-force eccentric resistance exercise with aerobic exercise only for people with type 2 diabetes mellitus.

Authors:  Robin L Marcus; Sheldon Smith; Glen Morrell; Odessa Addison; Leland E Dibble; Donna Wahoff-Stice; Paul C Lastayo
Journal:  Phys Ther       Date:  2008-09-18

Review 3.  Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?

Authors:  Jochen Antel; Özgür Albayrak; Gerd Heusch; Tobias Banaschewski; Johannes Hebebrand
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-08-23       Impact factor: 5.270

4.  Predicting blood pressure outcomes using single-item physician-administered measures: a retrospective pooled analysis of observational studies in Belgium.

Authors:  Lorenzo Villa; Diana Sun; Kris Denhaerynck; Stefaan Vancayzeele; Heidi Brié; Christine Hermans; Ann Aerts; Michael Levengood; Karen MacDonald; Ivo Abraham
Journal:  Br J Gen Pract       Date:  2015-01       Impact factor: 5.386

5.  Management of atherothrombotic risk factors in high-risk Canadian outpatients.

Authors:  Alan Bell; Michael D Hill; Robert J Herman; Manon Girard; Eric Cohen
Journal:  Can J Cardiol       Date:  2009-06       Impact factor: 5.223

6.  Influence of dyslipidemia in control of arterial hypertension among type-2 diabetics in the western region of the Republic of Macedonia.

Authors:  Ylber Jani; Amet Kamberi; Fatmir Ferati; Atila Rexhepi; Bekim Pocesta; Nikola Orovcanec; Dali Lala; Gafur Polisi; Mair Iseni; Arben Mirto; Agim Zeqiri
Journal:  Am J Cardiovasc Dis       Date:  2014-06-28

7.  Cardiovascular risk factors for incident hypertension in the prehypertensive population.

Authors:  Soo Jeong Kim; Jakyoung Lee; Sun Ha Jee; Chung Mo Nam; Kihong Chun; Il Soo Park; Soon Young Lee
Journal:  Epidemiol Health       Date:  2010-05-01

8.  Racial differences in response to antihypertensive therapy: does one size fits all?

Authors:  Ajay K Gupta
Journal:  Int J Prev Med       Date:  2010

9.  Characterization of vascular disease risk in postmenopausal women and its association with cognitive performance.

Authors:  N Maritza Dowling; Carey E Gleason; Joann E Manson; Howard N Hodis; Virginia M Miller; Eliot A Brinton; Genevieve Neal-Perry; M Nanette Santoro; Marcelle Cedars; Rogerio Lobo; George R Merriam; Whitney Wharton; Frederick Naftolin; Hugh Taylor; S Mitchell Harman; Sanjay Asthana
Journal:  PLoS One       Date:  2013-07-17       Impact factor: 3.240

Review 10.  Deregulation of RGS2 in cardiovascular diseases.

Authors:  Sharon Tsang; Anthony Yiu-Ho Woo; Weizhong Zhu; Rui-Ping Xiao
Journal:  Front Biosci (Schol Ed)       Date:  2010-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.